{
    "clinical_study": {
        "@rank": "18381", 
        "arm_group": [
            {
                "arm_group_label": "BRCAmut carrier relatives of the BRCAmut PDAC patient", 
                "description": "Who have no known prior or active personal history of non-PDAC malignancy (e.g. breast or ovarian cancer)"
            }, 
            {
                "arm_group_label": "BRCAmut carrier relatives of the BRCA mutation PDAC", 
                "description": "Patient with known prior or active breast and/or ovarian cancer"
            }, 
            {
                "arm_group_label": "BRCAmut carriers", 
                "description": "who are not related to a BRCAmut PDAC patient"
            }, 
            {
                "arm_group_label": "AJ PDAC patients", 
                "description": "who are proven non-BRCAmut carriers."
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood specimens tumor tissue samples will be requested"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to better understand why pancreatic cancer develops in some\n      people who are known carriers of the gene mutation (an abnormality) called BRCA, or its\n      close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2\n      mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer)\n      Registry. A registry is a database of information."
        }, 
        "brief_title": "A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma", 
        "condition": "Pancreatic Ductal Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma, Ductal, Breast"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BRCA mutation carrier is defined as a person with any mutation of the BRCA gene,\n             including BRCA1, or BRCA2. PALB2mut patients are also eligible.\n\n          -  Relative of a BRCA PDAC patient is defined as a first-degree relative, which\n             includes, parents, siblings or children.\n\n        BRCAmut PDAC Group: Study Group\n\n          -  Known BRCA mutation carrier.\n\n          -  Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).\n\n          -  Histologic proof of primary pancreatic ductal adenocarcinoma (at MSKCC or at a\n             participating center).\n\n          -  May have either potentially curable (resectable) primary PDAC, localized but\n             unresectable primary PDAC, or metastatic (stage IV) PDAC.\n\n          -  Prior personal history of other malignancy; either prior or currently active,\n             including breast or ovarian cancer is allowed.\n\n          -  Both previously treated and previously untreated patients are eligible. Previous\n             treatment may include surgical resection, regional radiation therapy, or systemic\n             therapy. Patient may be receiving active therapy.\n\n          -  Willing to provide blood specimens for correlative studies.\n\n          -  Willing to provide permission to obtain banked tumor tissue for analysis (previous\n             biopsies or surgical material). New tumor biopsies are not required for entrance into\n             the Registry.\n\n        BRCA mutation carrier, relative of a BRCA PDAC patients, without PDAC or other BRCAmut\n        related malignancy: (Control Cohort 1)\n\n          -  Known BRCA mutation carrier.\n\n          -  Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).\n\n          -  No current or prior history of PDAC.\n\n          -  Relative of a BRCAmut PDAC patient; no prior or active personal history of breast or\n             ovarian cancer.\n\n          -  Willing to provide blood specimens for correlative studies.\n\n        BRCAmut Carrier relative of BRCAmut PDAC patient with prior or active BRCAmut related\n        malignancy (Control Cohort 2):\n\n          -  Known BRCA mutation carrier.\n\n          -  Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).\n\n          -  No current or prior history of PDAC.\n\n          -  Relative of a BRCAmut PDAC patient.\n\n          -  Prior or active personal history of breast or ovarian cancer.\n\n          -  Willing to provide blood specimens for correlative studies.\n\n        BRCAmut carrier who is not related to a BRCAmut PDAC patient: (Control cohort 3) Known\n        BRCAmut carrier.\n\n          -  Ashkenazi Jewish decent (at least one parent of Ashkenazi Jewish origin).\n\n          -  No current or prior personal history of PDAC.\n\n          -  Prior personal history of other malignancy including breast or ovarian cancer is\n             allowed.\n\n          -  Willing to provide blood specimens for correlative studies.\n\n        Non-BRCAmut carriers with histologically proven PDAC: (Control cohort 4) Tested for and\n        negative for the BRCA founder mutations.\n\n          -  Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).\n\n          -  Not related to known BRCAmut carrier.\n\n          -  Histologic proof of primary pancreatic ductal adenocarcinoma (at MSKCC or at a\n             participating center). May have either potentially curable (resectable) primary PDAC,\n             localized but unresectable primary PDAC, or metastatic (stage IV) PDAC.\n\n          -  Both previously treated and previously untreated patients are eligible. Previous\n             treatment may include surgical resection, regional radiation therapy, or systemic\n             therapy. Patient may be receiving active therapy.\n\n          -  Willing to provide blood specimens for correlative studies.\n\n          -  Willing to provide permission to obtain banked tumor tissue for analysis (previous\n             biopsies or surgical material). New tumor biopsies are not required for entrance into\n             the Registry\n\n        Exclusion Criteria:\n\n          -  Individuals will be excluded from the Registry if they:\n\n          -  Are unable to sign informed consent for medical or other reasons. Do not speak\n             English (MSK and UPenn) or do not speak English or Hebrew (BCGC Sites).\n\n          -  Are under 21 years of age.\n\n          -  Not willing to provide blood samples for correlative studies."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "BRCA mutation carriers with PDAC will be identified by the PIs, co-investigators and by\n        the research staff at MSK, UPenn, and the Israeli BCGC sites"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983410", 
            "org_study_id": "13-217"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BRCAmut carrier relatives of the BRCAmut PDAC patient", 
                    "BRCAmut carrier relatives of the BRCA mutation PDAC", 
                    "BRCAmut carriers", 
                    "AJ PDAC patients"
                ], 
                "intervention_name": "The risk assessment questionnaire", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "BRCAmut carrier relatives of the BRCAmut PDAC patient", 
                    "BRCAmut carrier relatives of the BRCA mutation PDAC", 
                    "BRCAmut carriers", 
                    "AJ PDAC patients"
                ], 
                "intervention_name": "Blood specimens", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "BRCAmut carriers", 
                    "AJ PDAC patients"
                ], 
                "intervention_name": "tumor tissue samples will be requested", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "BRCA Mutation Carriers", 
            "PDAC carriers", 
            "BRCAmut carriers", 
            "Registry", 
            "13-217"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "David Kelsen, MD", 
                    "phone": "646-888-4179"
                }, 
                "contact_backup": {
                    "last_name": "Kenneth Yu, MD", 
                    "phone": "646-888-4188"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "David Kelsen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Susan Domchek, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4283"
                    }, 
                    "name": "Abramson Cancer Center at University of Pennsylvania Medical Center"
                }, 
                "investigator": {
                    "last_name": "Susan Domchek, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ephrat Levy-Lahad, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel"
                    }, 
                    "name": "Shaare Zedek Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ephrat Levy-Lahad, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Talia Golan, MD"
                }, 
                "contact_backup": {
                    "last_name": "Eitan Friedman, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel Hashomer", 
                        "country": "Israel"
                    }, 
                    "name": "Sheba Medical Center"
                }, 
                "investigator": {
                    "last_name": "Talia Golan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Israel"
            ]
        }, 
        "number_of_groups": "4", 
        "official_title": "A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma", 
        "overall_contact": {
            "last_name": "David Kelsen, MD", 
            "phone": "646-888-4179"
        }, 
        "overall_contact_backup": {
            "last_name": "Kenneth Yu, MD", 
            "phone": "646-888-4188"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "David Kelsen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Establishment of a BRCA mutation carriers PDAC Registry with appropriate control groups, and collection and storage of biological material for future studies.", 
            "measure": "prospective Registry", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983410"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shaare Zedek Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sheba Medical Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "May 2014"
    }
}